[Practical update of total dose compensation in case of temporary interruption of external radiotherapy in the COVID-19 pandemic context].

Compensation de la dose totale en cas d’interruption temporaire de radiothérapie externe dans le contexte de la pandémie de COVID-19 : mise au point pratique.

Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 06 04 2020
accepted: 07 04 2020
pubmed: 21 4 2020
medline: 11 6 2020
entrez: 21 4 2020
Statut: ppublish

Résumé

Overall treatment time is an important factor of local recurrence and indirectly of distant evolution, namely in case of protracted treatments. The current pandemic impacts on the duration of radiotherapy if patients under treatments and synchronously suffering from COVID-19. The models used to compensate the total dose in case of temporary treatment interruption are well known but it is of importance in that pandemic context to update and homogenize clinical practice in order to improve local control without increasing normal tissue complications.

Identifiants

pubmed: 32307313
pii: S1278-3218(20)30096-2
doi: 10.1016/j.canrad.2020.04.001
pmc: PMC7146696
pii:
doi:

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

182-187

Informations de copyright

Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

Références

Rep Pract Oncol Radiother. 2015 Sep-Oct;20(5):328-39
pubmed: 26549990
Radiother Oncol. 1992 Aug;24(4):215-20
pubmed: 1410576
PLoS One. 2019 Jul 22;14(7):e0218627
pubmed: 31329602
Radiother Oncol. 2010 Jul;96(1):6-12
pubmed: 20400191
J Med Imaging Radiat Oncol. 2018 Feb;62(1):116-121
pubmed: 29030906
Radiother Oncol. 2020 Jan;142:210-216
pubmed: 31431371
J Clin Oncol. 2005 Jan 1;23(1):11-6
pubmed: 15545665
Ann Surg Oncol. 2020 Mar 17;:
pubmed: 32185537
Radiat Oncol. 2018 May 16;13(1):96
pubmed: 29769103
Radiother Oncol. 2020 Feb;143:58-65
pubmed: 31439448
Lancet Oncol. 2010 Mar;11(3):258-65
pubmed: 20138810
Cancer Radiother. 2016 Sep;20 Suppl:S4-7
pubmed: 27521032
Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1165-7
pubmed: 10939883
Br J Radiol. 2000 Aug;73(872):892-4
pubmed: 11026867
JCO Clin Cancer Inform. 2017 Nov;1:1-15
pubmed: 30657372
Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):667-71
pubmed: 15927409
Crit Rev Oncol Hematol. 2015 Mar;93(3):312-9
pubmed: 25497158
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):654-61
pubmed: 17467926
Radiother Oncol. 2011 Aug;100(2):282-8
pubmed: 21367477
Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):516-7
pubmed: 10661362
Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1353-60
pubmed: 16765531
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):832-833
pubmed: 29485054
J Clin Oncol. 2005 Jan 1;23(1):24-9
pubmed: 15545669
Clin Oncol (R Coll Radiol). 2002 Oct;14(5):382-93
pubmed: 12555877
Radiother Oncol. 2011 Apr;99(1):6-11
pubmed: 21458088
Clin Oncol (R Coll Radiol). 1996;8(5):297-307
pubmed: 8934049
Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1275-88
pubmed: 7635767
Cancer Radiother. 2020 Apr;24(2):87
pubmed: 32299663
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):841-842
pubmed: 29485058
Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):493-8
pubmed: 8226140
Cancer. 2005 Jul 15;104(2):240-50
pubmed: 15948160
Radiother Oncol. 1985 Jan;3(1):1-9
pubmed: 3975436
J Clin Oncol. 2006 Mar 1;24(7):1057-63
pubmed: 16505424

Auteurs

D Azria (D)

IRCM, Institut de recherche en cancérologie de Montpellier (U1194), 208, avenue des Apothicaires, 34298 Montpellier cedex 5, France; Inserm, U1194, 208, avenue des Apothicaires, 34298 Montpellier cedex 5, France; Université de Montpellier, centre de recherche U1194, 208, avenue des Apothicaires, 34298 Montpellier cedex 05, France; Fédération universitaire d'oncologie radiothérapie, ICM, institut régional du cancer de Montpellier, rue Croix-Verte, 34298 Montpellier cedex 05, France. Electronic address: david.azria@icm.unicancer.fr.

C Hennequin (C)

Service de cancérologie-radiothérapie, AP-HP, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris, France.

P Giraud (P)

Service d'oncologie radiothérapie, AP-HP, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université de Paris, 20, rue Leblanc, 75015 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH